About Galleon:
Galleon is positioned to be the leader in the discovery and development of Breathing Control Medicines
Recent scientific breakthroughs in understanding how the human body controls breathing are driving development at Galleon.
Breathing control disorders, resulting from conditions such as sleep apnea, surgical anesthesia, lung & heart disease, obesity and diabetics can affect nearly 30% of the population.
In late 2011 we expect clinical proof-of-concept data from three IND-ready development candidates to address this large, underdeveloped market opportunity.
Galleon’s strategy is to capitalize on the opportunity to produce first and best-in-class products utilizing our unique and proven purpose-built, integrated drug discovery platform.
NEW MARKETS
Galleon focuses of breathing control conditions because these worldwide markets have documented physician and patient demand and very little competition. We are making post-surgical care safer, more comfortable and more cost-effective. For sleep apnea patients we are creating an alternative to wearing a mask during sleep. For COPD patients with acute worsening of symptoms we are decreasing the need for a mechanical ventilator. For chronic pain patients we are making their treatment safer and more effective. Premature babies will be discharged faster from intensive care units.
NEW PRODUCTS
Galleon’s product pipeline addresses the needs of both acute and chronic care patients. Our three lead products are now entering clinical trials and there are successor compounds under evaluation in Galleon’s unique, purpose-built drug discovery platforms. Our platform will produce a stream of products for at least a decade.
NEW PATHWAYS
The body’s breathing control system is complicated. But for the last five years Galleon scientists have been using modern scientific tools to create a productive and cost-efficient drug discovery platform. We are now uniquely positioned to take advantage of a steady stream of breakthroughs in the breathing control sciences. Our pathways are a mix of those previously validated in man and recent scientific advances.